I disagree. The company has a tiny market cap and already with AXIM a vast range of products at their disposal without the massive R & D spend.
Furthermore have you overlooked where they said they were looking to collaborate on development projects. This was made clearer in the AXIM press release.
I think cultivation is going to prove difficult to monetise and is in fact becoming unnecessary . Why have a grow room to cultivate a particular strain when modern extraction doesn’t require it?
I think the whole cultivation space will commoditise.
Ted
- Forums
- ASX - By Stock
- IHL
- Maybe best VALUE Health/Med Cannabis Opp EVER
Maybe best VALUE Health/Med Cannabis Opp EVER, page-5
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)